Compare Summit Therapeutics Inc (SMMT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Sanofi SA — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 10× Summit Therapeutics Inc's market cap, and Sanofi SA pays a 5.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | SNY | |
|---|---|---|
Market Cap | $10.48B | $104.83B |
Sector | Health | Health |
52-Week High | $29.32 | $52.34 |
52-Week Low | $13.05 | $41.33 |
Enterprise Value | $9.90B | $121.32B |
Dividend Yield | — | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
